Candel Therapeutics, Inc. CADL Deferred Offering Issuance Costs In Accounts Payable And Accrued Expenses
Deferred Offering Issuance Costs In Accounts Payable And Accrued Expenses at other companies
Other financials
Where this comes from
Reported directly by Candel Therapeutics, Inc. in its filing.
Tagged under the XBRL concept cadl:DeferredOfferingIssuanceCostsInAccountsPayableAndAccruedExpenses.
The official record: Candel Therapeutics, Inc.’s 10-K, filed March 12, 2026, on SEC EDGAR. View the filing →
Ask your AI about Candel Therapeutics, Inc.'s deferred offering issuance costs in accounts payable and accrued expenses.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Candel Therapeutics, Inc.'s deferred offering issuance costs in accounts payable and accrued expenses?
- Candel Therapeutics, Inc. (CADL) reported deferred offering issuance costs in accounts payable and accrued expenses of $23.25K in Q4 2025.
- What does deferred offering issuance costs in accounts payable and accrued expenses mean?
- This metric tracks costs related to equity or debt offerings that have been incurred but not yet paid, recorded within accounts payable. It provides visibility into the short-term liabilities associated with capital-raising activities that will impact future cash flows.